Skip to main content

Miquel Vila Bover

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Miquel Vila Bover

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder.

In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN).

I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.

Projects

Muerte celular programada como diana terapéutica en la enfermedad de Parkinson

IP: Miquel Vila Bover
Collaborators: Laia Perez Lasarte
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 180400
Reference: RYC-2005-1561
Duration: 12/07/2006 - 31/10/2011

Ministerio de Ciencia

Targeting programmed cell death in Paarkinson's disease (Targeting PCD in PD)

IP: -
Collaborators: Miquel Vila Bover
Funding agency: EUROPEAN COMMISSION
Funding:
Reference: MEXT-CT-2005-024929
Duration: 01/12/2005 - 30/11/2009

Targetting programmed cell death in Parkinson's disease (Targeting PCD in PD) Grant Agreement No 024929 Contract MEXC-CT-2005-024929 Marie Curie Excellence Grants

IP: Miquel Vila Bover
Collaborators: Jordi Bove Badell
Funding agency: EUROPEAN COMMISSION
Funding: 1151774.03
Reference: FP6-PEOPLE-PCD-IN-PD-24929
Duration: 01/12/2005 - 01/12/2009

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Sebastian Lazaro

Sebastian Lazaro

Research technician
Genetics Medicine
Read more
Anna Llort Sales

Anna Llort Sales

Childhood Cancer and Blood Disorders
Read more
Marc Simo Perdigo

Marc Simo Perdigo

Molecular Medical Imaging
Read more
Joaquim Sola  Santesmases

Joaquim Sola Santesmases

Zelador/a
General Services and Infrastructures Unit
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.